Deep Vein Thrombosis (DVT) – Pipeline Insight, 2018

Deep Vein Thrombosis (DVT) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2023-2030)

<h1>Deep Vein Thrombosis Pipeline Analysis</h1><ul><li>The “Deep Vein Thrombosis (DVT) – Pipeline Insights 2018″ report covers an in-depth analysis of DVT drug molecules currently undergoing clinical studies. It provides a deep understanding of potential DVT drug molecules across all drug development phases.</li><li>The report assesses the pipeline DVT molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products) molecule type (small molecules, biologics) and route of administration (oral, IV, and others).</li><li>The report provides a snapshot of discontinued and dormant drugs too. In addition, the report includes key insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.</li><li>The report covers company profiles key players in developing DVT drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.</li></ul><p> </p><h2>The scope of the report</h2><p style="padding-left: 30px;">• Provides comprehensive understanding of active DVT pipeline drug candidates<br/> • Includes all-inclusive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.<br/> • Offers pipeline assessment by monotherapy, combination therapy products, and route of administration<br/> • Provides a comparative analysis of key marketed products and pipeline drug candidates<br/> • Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators<br/> • Provides key info on players involved in clinical R&amp;D of DVT drug candidates.<br/> • Provides in-depth coverage of key news related to DVT drug molecules, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.</p><p> </p><h2>Why should I purchase this report</h2><p style="padding-left: 30px;">• To obtain an understanding of the current DVT pipeline landscape.<br/> • To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.<br/> • To valuably optimize R&amp;D activities in-line with robust therapeutic drug markets.<br/> • To devise strategic initiatives by identifying prospective partners with progressing projects.</p>

<h2>Deep Vein Thrombosis Pipeline Analysis</h2><ul><li>Deep vein thrombosis is the formation of blood clot in a vein in the body. Maximum clots of the deep vein occur in the legs. </li><li>It can cause pain and redness in the legs along with swelling in the lower leg (ankle and foot). It is a member of venous thromboembolism (VTE). </li><li>This blockage of blood vessels leads to low oxygen levels in the blood, causing damage to the lungs known as pulmonary embolism. Generally, anticoagulation therapy is used for the treatment of DVT, whereas procedures such as thrombolysis and placement of inferior vena cava filters are also used in a unique situation.</li><li>In the present drug pipeline, the most preferred route of administration remains through the oral mode, with around 43% of the pipeline molecules administered through this mode. Edoxaban was approved in 2015. Heparin, Enoxaparin are in early phase and phase 1 clinical trials of development. Biologicals like Alteplase (recombinant t-PA), Apixaban, Warfarin are in phase 2 trails, and Xarelto, Rivaroxaban, Tinzaparin, Enoxaparin are in period three stages of development. </li><li>Of all the stages of development, more percentage of drugs are found to be in the late stage of clinical development. Which upon successful completion can, therefore, be expected to hit the market shortly.</li><li>Globally, development of efficient and advanced technology, increase in the awareness among people regarding existing treatments for venous thromboembolism, increasing government initiatives across the globe, growing prevalence and incidence rate of venous thromboembolism are the prime growth drivers of the venous thromboembolism treatment market.</li><li> Despite, higher cost of the research and development, and complex government regulatory approvals, an increase in adoption of venous thromboembolism treatment in emerging economies such as China, India, and others, has gained focus of the researchers to develop products in this area.</li></ul>